

Michael Maeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4459634/publications.pdf>

Version: 2024-02-01

245
papers

13,120
citations

41344

49
h-index

24982

109
g-index

285
all docs

285
docs citations

285
times ranked

10928
citing authors

#	ARTICLE	IF	CITATIONS
1	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	27.0	1,099
2	Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2013, 369, 1587-1597.	27.0	943
3	Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. <i>New England Journal of Medicine</i> , 2017, 376, 1813-1823.	27.0	740
4	Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. <i>Circulation</i> , 2006, 114, 1955-1961.	1.6	666
5	Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2016, 388, 2743-2752.	13.7	620
6	System Delay and Mortality Among Patients With STEMI Treated With Primary Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 763.	7.4	519
7	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1619-1629.	2.8	401
8	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	2.2	366
9	Outcomes 1 Year after Thrombus Aspiration for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1111-1120.	27.0	337
10	2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents. <i>Journal of the American College of Cardiology</i> , 2009, 53, 658-664.	2.8	316
11	Randomized Comparison of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation in Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting. <i>Circulation</i> , 2011, 123, 79-86.	1.6	269
12	Routine Thrombectomy in Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2006, 114, 40-47.	1.6	242
13	Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2007, 50, 463-470.	2.8	229
14	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 1415-1424.	13.7	223
15	Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. <i>Lancet, The</i> , 2021, 397, 985-995.	13.7	208
16	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. <i>Lancet, The</i> , 2010, 375, 1090-1099.	13.7	198
17	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. <i>Lancet, The</i> , 2013, 381, 661-669.	13.7	173
18	Long-Term Results After Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2013, 62, 30-34.	2.8	168

#	ARTICLE	IF	CITATIONS
19	Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007107.	2.6	157
20	Randomized Comparison of Coronary Bifurcation Stenting With the Crush Versus the Culotte Technique Using Sirolimus Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 27-34.	3.9	156
21	Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1246-1255.	1.6	149
22	Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. <i>Clinical Epidemiology</i> , 2010, 2, 137.	3.0	147
23	Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2289-2301.	2.8	123
24	Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 751-762.	2.8	116
25	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1437-1449.	2.9	111
26	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	13.7	107
27	Effect of Ischemic Postconditioning During Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 490.	6.1	105
28	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	104
29	Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. <i>European Heart Journal</i> , 2016, 37, 1923-1928.	2.2	103
30	The EBC TWO Study (European Bifurcation Coronary TWO). <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	102
31	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2014, 383, 2047-2056.	13.7	96
32	Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 565-574.	2.9	91
33	The Western Denmark Heart Registry. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1259-1272.	2.8	90
34	Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2622-2632.	2.8	89
35	Primary Angioplasty Versus Fibrinolysis in Acute Myocardial Infarction. <i>Circulation</i> , 2010, 121, 1484-1491.	1.6	83
36	Impact of Side Branch Modeling on Computation of Endothelial Shear Stress in Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 125-135.	2.8	75

#	ARTICLE	IF	CITATIONS
37	Hypothermia during reperfusion does not reduce myocardial infarct size in pigs. <i>Basic Research in Cardiology</i> , 2006, 101, 61-68.	5.9	72
38	The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. <i>European Heart Journal</i> , 2007, 29, 1259-1266.	2.2	71
39	Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with ST-segment elevation myocardial infarction: From the Western Denmark heart registry. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 912-919.	1.7	68
40	Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model. <i>BMC Cardiovascular Disorders</i> , 2009, 9, 31.	1.7	65
41	Side branch fractional flow reserve measurements after main vessel stenting: a Nordic-Baltic Bifurcation Study III substudy. <i>EuroIntervention</i> , 2012, 7, 1155-1161.	3.2	59
42	Negative vascular remodelling after implantation of bioabsorbable magnesium alloy stents in porcine coronary arteries: a randomised comparison with bare-metal and sirolimus-eluting stents. <i>Heart</i> , 2008, 95, 241-246.	2.9	57
43	Comparison of the Sirolimus-Eluting Versus Paclitaxel-Eluting Coronary Stent in Patients With Diabetes Mellitus: The Diabetes and Drug-Eluting Stent (DiabeDES) Randomized Angiography Trial – A list of participating centers and investigators appears in the Appendix.. <i>American Journal of Cardiology</i> , 2009, 103, 345-349.	1.6	55
44	Layered Fibrotic Plaques Are the Predominant Component in Cardiac Allograft Vasculopathy. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 773-784.	5.3	55
45	Nonculprit Stenosis Evaluation Using Instantaneous Wave-Free Ratio in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2528-2535.	2.9	55
46	Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2012, 109, 629-635.	1.6	54
47	Randomised comparison of manual compression and FemoSeal [®] vascular closure device for closure after femoral artery access coronary angiography: the CLOSure dEVICES Used in everyday Practice (CLOSE-UP) study. <i>EuroIntervention</i> , 2014, 10, 183-190.	3.2	54
48	System Delay and Timing of Intervention in Acute Myocardial Infarction (from the Danish Acute) Tj ETQqO 0 0 rgBT /Qverlock 10 Tf 50 30	1.6	52
49	Clinical Outcome After Crush Versus Culotte Stenting of Coronary Artery Bifurcation Lesions. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1160-1165.	2.9	51
50	Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial). <i>American Journal of Cardiology</i> , 2012, 110, 1585-1591.	1.6	48
51	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 2052-2063.	1.6	48
52	Time to Treatment and Three-Year Mortality After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction – a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) Substudy. <i>American Journal of Cardiology</i> , 2010, 105, 1528-1534.	1.6	45
53	Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 405-414.	1.2	45
54	Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with ST-segment elevation myocardial infarction – An iSTEMI substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 686-692.	1.7	45

#	ARTICLE	IF	CITATIONS
55	3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 812-818.	2.9	43
56	Danish study of Non-Invasive testing in Coronary Artery Disease (Dan-NICAD): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 262.	1.6	43
57	The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis). <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2029-2037.	2.9	43
58	Intravascular ultrasound assessment of remodelling and reference segment plaque burden in type-2 diabetic patients. <i>European Heart Journal</i> , 2007, 28, 1759-1764.	2.2	42
59	2-Year Patient-Related Versus Stent-Related Outcomes. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1140-1147.	2.8	42
60	Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. <i>EuroIntervention</i> , 2010, 5, 898-905.	3.2	42
61	Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark. <i>American Journal of Cardiology</i> , 2010, 105, 1513-1519.	1.6	41
62	Co-registration of optical coherence tomography and X-ray angiography in percutaneous coronary intervention. The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) fusion study. <i>International Journal of Cardiology</i> , 2015, 182, 272-278.	1.7	41
63	Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. <i>European Heart Journal</i> , 2019, 40, 167-176.	2.2	40
64	Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. <i>European Heart Journal</i> , 2008, 29, 2733-2741.	2.2	39
65	Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy). <i>American Journal of Cardiology</i> , 2011, 108, 1232-1237.	1.6	39
66	16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 847-854.	2.2	39
67	Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 255-264.	2.9	38
68	Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. <i>Diabetes Care</i> , 2017, 40, 1103-1110.	8.6	37
69	Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease. <i>EuroIntervention</i> , 2012, 8, 456-464.	3.2	37
70	Clinical Validation of a Virtual Planner for Coronary Interventions Based on Coronary CT Angiography. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 1242-1255.	5.3	36
71	Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. <i>Open Heart</i> , 2020, 7, e000947.	2.3	34
72	Evaluation and Management of Nonculprit Lesions in STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1145-1154.	2.9	33

#	ARTICLE	IF	CITATIONS
73	Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2162-2170.	3.4	32
74	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3347-3354.	2.0	32
75	Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. <i>Rheumatology</i> , 2021, 60, 1400-1409.	1.9	32
76	Comparison of Stent Thrombosis, Myocardial Infarction, and Mortality Following Drug-Eluting Versus Bare-Metal Stent Coronary Intervention in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 102, 165-172.	1.6	31
77	Clinical Outcome After Primary Percutaneous Coronary Intervention With Drug-Eluting and Bare Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 176-184.	3.9	30
78	Evaluation of algorithms for registry-based detection of acute myocardial infarction following percutaneous coronary intervention. <i>Clinical Epidemiology</i> , 2016, Volume 8, 415-423.	3.0	30
79	Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12915.	3.4	30
80	5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve. <i>Journal of the American College of Cardiology</i> , 2022, 79, 965-974.	2.8	30
81	Lack of acute cardioprotective effect from preischemic erythropoietin administration in a porcine coronary occlusion model. <i>Clinical Physiology and Functional Imaging</i> , 2005, 25, 305-310.	1.2	28
82	Three-Year Outcomes After Revascularization With Everolimus- and Sirolimus-Eluting Stents From the SORT OUT IV Trial. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 840-848.	2.9	28
83	Comparison of Intravascular Ultrasound and Angiographic Assessment of Coronary Reference Segment Size in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 101, 590-595.	1.6	27
84	Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 100.	1.7	27
85	Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 624-633.	2.9	27
86	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1989-1999.	3.4	26
87	Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial. <i>Circulation</i> , 2021, 143, 2155-2165.	1.6	25
88	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. <i>American Heart Journal</i> , 2011, 162, 740-747.	2.7	24
89	Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 101-108.	1.7	23
90	Coronary artery disease and risk of adverse cardiac events and stroke. <i>European Journal of Clinical Investigation</i> , 2017, 47, 819-828.	3.4	23

#	ARTICLE	IF	CITATIONS
91	Detection of early changes in the coronary artery microstructure after heart transplantation: A prospective optical coherence tomography study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 486-495.	0.6	23
92	Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial. <i>EuroIntervention</i> , 2011, 7, 323-331.	3.2	23
93	Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 170, 70-78.	2.7	21
94	Severe Mental Illness and Clinical Outcome After Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 120, 550-555.	1.6	21
95	Association of Coronary Plaque With Low-Density Lipoprotein Cholesterol Levels and Rates of Cardiovascular Disease Events Among Symptomatic Adults. <i>JAMA Network Open</i> , 2022, 5, e2148139.	5.9	21
96	The impact of acquisition angle differences on three-dimensional quantitative coronary angiography. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 214-222.	1.7	20
97	The natural history of collagen and α -actin expression after coronary angioplasty. <i>Cardiovascular Pathology</i> , 2004, 13, 260-267.	1.6	19
98	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. <i>American Heart Journal</i> , 2014, 167, 459-465.e1.	2.7	19
99	Timing, Causes, and Predictors of Death After Three Years' Follow-Up in the Danish Multicenter Randomized Study of Fibrinolysis Versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) Trial. <i>American Journal of Cardiology</i> , 2009, 104, 210-215.	1.6	18
100	CAD Is an Independent Risk Factor for Stroke Among Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2540-2542.	2.8	18
101	Comparison of Outcomes of Patients ≥ 80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , 2017, 70, 1395-1400.	1.6	17
102	Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial. <i>American Heart Journal</i> , 2015, 170, 210-215.	2.7	17
103	Two-year outcome after biodegradable polymer sirolimus- and biolimus-eluting coronary stents (from the ISAR-TRIPLE study). <i>Journal of the American College of Cardiology</i> , 2017, 70, 1395-1400.	3.2	17
104	The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. <i>EuroIntervention</i> , 2012, 8, 591-598.	3.2	17
105	Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. <i>Heart</i> , 2007, 93, 694-697.	2.9	16
106	Serial Intravascular Ultrasound Analysis of Peri-Stent Remodeling and Proximal and Distal Edge Effects After Sirolimus-Eluting or Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2009, 103, 1083-1088.	1.6	16
107	Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007381.	3.9	16
108	Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1182-1188.	0.9	16

#	ARTICLE	IF	CITATIONS
109	Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001803.	2.8	16
110	Interplay of Risk Factors and Coronary Artery Calcium for CHD Risk in Young Patients. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2387-2396.	5.3	16
111	Development and validation of an artificial neural network algorithm to predict mortality and admission to hospital for heart failure after myocardial infarction: a nationwide population-based study. <i>The Lancet Digital Health</i> , 2022, 4, e37-e45.	12.3	16
112	Quantitative coronary analysis in the Nordic Bifurcation studies. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 175-180.	1.5	15
113	Long-Term Outcome of Sirolimus-Eluting and Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (A Danish Organization for Randomized Trials on) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i>	1.4	15
114	Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. <i>Thrombosis and Haemostasis</i> , 2016, 116, 172-180.	3.4	15
115	Risk stratification by assessment of coronary artery disease using coronary computed tomography angiography in diabetes and non-diabetes patients: a study from the Western Denmark Cardiac Computed Tomography Registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1271-1278.	1.2	15
116	SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis. <i>Thorax</i> , 2021, 76, 370-379.	5.6	15
117	Intravascular Ultrasound Assessment of Expansion of the Sirolimus-Eluting (Cypher Select) and Paclitaxel-Eluting (Taxus Express-2) Stent in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 102, 19-26.	1.6	14
118	Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 161-170.	2.4	14
119	Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. <i>European Journal of Clinical Investigation</i> , 2012, 42, 266-274.	3.4	14
120	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. <i>Scientific Reports</i> , 2016, 6, 33054.	3.3	14
121	Editor's Choice-Acute versus subacute angiography in patients with non-ST-elevation myocardial infarction – the NONSTEMI trial phase I. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 490-499.	1.0	14
122	Rationale and design of the precise percutaneous coronary intervention plan (P3) study: Prospective evaluation of a virtual computed tomography-based percutaneous intervention planner. <i>Clinical Cardiology</i> , 2021, 44, 446-454.	1.8	14
123	Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. <i>Diabetes Care</i> , 2021, 44, 2353-2360.	8.6	14
124	Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. <i>EuroIntervention</i> , 2020, 15, 1451-1457.	3.2	14
125	Adventitial Myofibroblasts Play no Major Role in Neointima Formation After Angioplasty. <i>Scandinavian Cardiovascular Journal</i> , 2003, 37, 34-42.	1.2	13
126	Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: From Western Denmark heart registry. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 260-265.	1.7	13

#	ARTICLE	IF	CITATIONS
127	A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the diabledES IV randomized angiography trial). <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1161-1167.	1.7	13
128	<p>Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 419-428.	3.0	13
129	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2346-2355.	2.9	13
130	Nurse-led Motivational Telephone Follow-up After Same-day Percutaneous Coronary Intervention Reduces Readmission and Contacts to General Practice. <i>Journal of Cardiovascular Nursing</i> , 2019, 34, 222-230.	1.1	13
131	Myocardial perfusion imaging with ^{99m} Tc sestamibi early after reperfusion reliably reflects infarct size reduction by ischaemic preconditioning in an experimental porcine model. <i>Nuclear Medicine Communications</i> , 2004, 25, 495-500.	1.1	12
132	Pain and discomfort in closure of femoral access coronary angiography. The CLOSuredEvices Used in everyday Practice (CLOSE-UP) pain sub study. <i>European Journal of Cardiovascular Nursing</i> , 2014, 13, 221-226.	0.9	12
133	Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial. <i>American Heart Journal</i> , 2018, 202, 49-53.	2.7	12
134	Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 22-27.	4.0	12
135	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 192-199.	3.0	12
136	Estimated Pulse Wave Velocity Is Associated With All-Cause Mortality During 8.5 Years Follow-up in Patients Undergoing Elective Coronary Angiography. <i>Journal of the American Heart Association</i> , 2022, 11, e025173.	3.7	12
137	Long-term outcome following percutaneous coronary intervention with drug-eluting stents compared with bare-metal stents in saphenous vein graft lesions: From Western Denmark heart registry. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 1035-1042.	1.7	11
138	Regional systems-of-care for primary percutaneous coronary intervention in ST-elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2015, 26, 713-722.	0.7	11
139	Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 567-573.	1.7	11
140	Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction. <i>Heart</i> , 2020, 106, 24-32.	2.9	11
141	Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. <i>EuroIntervention</i> , 2017, 13, 1336-1344.	3.2	11
142	Effects of Levosimendan on Myocardial Infarct Size and Hemodynamics in a Closed-Chest Porcine Ischemia-Reperfusion Model. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 335-342.	2.6	10
143	Effects of pentoxifylline on the vascular response to injury after angioplasty in rabbit iliac arteries. <i>Basic Research in Cardiology</i> , 2008, 103, 257-264.	5.9	10
144	Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1047-1054.	3.4	10

#	ARTICLE	IF	CITATIONS
145	Safety of therapeutic hypothermia combined with primary percutaneous coronary intervention after out-of-hospital cardiac arrest. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 60-63.	1.0	10
146	Impact of thrombus aspiration during ST-Elevation Myocardial Infarction: a six month composite endpoint and risk of stroke analyses of the TASTE trial. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 62.	1.7	10
147	Comparison of Acute Versus Subacute Coronary Angiography in Patients With NON-ST-Elevation Myocardial Infarction (from the NONSTEMI Trial). <i>American Journal of Cardiology</i> , 2019, 124, 825-832.	1.6	10
148	Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomized SORT OUT IX trial. <i>American Heart Journal</i> , 2019, 213, 1-7.	2.7	10
149	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 153-158.	1.6	10
150	Smoking is the dominating modifiable risk factor in younger patients with STEMI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 70-75.	1.0	9
151	Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial. <i>Coronary Artery Disease</i> , 2020, 31, 485-492.	0.7	9
152	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 17-24.	0.8	9
153	Use of three-dimensional optical coherence tomography to verify correct wire position in a jailed side branch after main vessel stent implantation. <i>EuroIntervention</i> , 2011, 7, 528-529.	3.2	9
154	Comparison of MynxGrip vascular closure device and manual compression for closure after femoral access angiography: a randomized controlled trial: the closure devices used in every day practice study, CLOSE-UP III trial. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 68.	1.7	9
155	Nonsteroidal Antiinflammatory Drug Use and Cardiovascular Risks After Coronary Stent Implantation. <i>Pharmacotherapy</i> , 2011, 31, 458-468.	2.6	8
156	Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: The randomized diabetes and drug-eluting stent (DiabeDES) IV intravascular ultrasound trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 864-872.	1.7	8
157	Heart Failure and Ischemic Heart Disease in Patients With Rheumatoid Arthritis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3069-3071.	2.8	8
158	Association between anti-diabetes treatments and cardiovascular risk in diabetes patients with and without coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 351-359.	2.0	8
159	Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. <i>EuroIntervention</i> , 2014, 10, 212-223.	3.2	8
160	Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS ₂ -P2A2RC score. <i>European Heart Journal</i> , 2022, 43, 996-1004.	2.2	8
161	Myocardial cooling for reperfusion injury protection achieved by organ specific hypothermic autologous perfusion. <i>Scandinavian Cardiovascular Journal</i> , 2003, 37, 297-303.	1.2	7
162	Positive Predictive Value of Clinically Suspected ST-Segment Elevation Myocardial Infarction Using Angiographic Verification. <i>American Journal of Cardiology</i> , 2013, 112, 923-927.	1.6	7

#	ARTICLE	IF	CITATIONS
163	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 40-48.	1.6	7
164	Renin-Ângiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017297.	3.7	7
165	Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial. <i>EuroIntervention</i> , 2022, 18, e124-e131.	3.2	7
166	Lack of cardioprotection from metabolic support with glutamine or glutamate in a porcine coronary occlusion model. <i>Scandinavian Cardiovascular Journal</i> , 2005, 39, 115-120.	1.2	6
167	Staged re-evaluation of non-culprit lesions in ST segment elevation myocardial infarction: a retrospective study. <i>Open Heart</i> , 2016, 3, e000427.	2.3	6
168	Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2019, 124, 671-677.	1.6	6
169	Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 23.	6.8	6
170	Ten-year outcomes from a randomised comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study. <i>EuroIntervention</i> , 2019, 15, e1022-e1024.	3.2	6
171	Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100301.	5.6	6
172	Coronary Edema Demonstrated by Cardiovascular Magnetic Resonance in Patients With Peri-Stent Inflammation and Aneurysm Formation After Treatment by Drug-Eluting Stents. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 352-354.	2.6	5
173	Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. <i>Endoscopy International Open</i> , 2016, 04, E527-E533.	1.8	5
174	Myocardial infarction with non-obstructive thrombus validated by optical coherence tomography. <i>Scandinavian Cardiovascular Journal</i> , 2017, 51, 61-68.	1.2	5
175	Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 329-338.	1.2	5
176	Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1199-1210.	1.5	5
177	Predicting stroke in patients without atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13103.	3.4	5
178	Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). <i>American Journal of Cardiology</i> , 2020, 125, 349-353.	1.6	5
179	Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: A study from the Western Denmark Heart Registry. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412094180.	2.0	5
180	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , 2021, 136, 106809.	2.1	5

#	ARTICLE	IF	CITATIONS
181	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC: Cardiovascular Interventions, 2021, 14, 768-780.	2.9	5
182	Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. EuroIntervention, 2019, 15, 700-706.	3.2	5
183	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	5
184	A phase of increased ST elevation during coronary occlusion following ischemic preconditioning. Basic Research in Cardiology, 2006, 101, 140-148.	5.9	4
185	Deliver the drug and be resorbed: evidence from ABSORB Japan. European Heart Journal, 2015, 36, 3343-3345.	2.2	4
186	ST Elevation Infarction after Heart Transplantation Induced by Coronary Spasms and Mural Thrombus Detected by Optical Coherence Tomography. Case Reports in Transplantation, 2016, 2016, 1-4.	0.3	4
187	Agreement between nonculprit stenosis follow-up iFR and FFR after STEMI (iSTEMI substudy). BMC Research Notes, 2020, 13, 410.	1.4	4
188	Instantaneous wave-free ratio guided multivessel revascularisation during percutaneous coronary intervention for acute myocardial infarction: study protocol of the randomised controlled iMODERN trial. BMJ Open, 2021, 11, e044035.	1.9	4
189	Microvascular disease increases the risk of lower limb amputation – A Western Danish cohort study. European Journal of Clinical Investigation, 2022, 52, e13812.	3.4	4
190	Association between REDUCE-IT criteria, coronary artery disease severity, and cardiovascular events: the Western Denmark Heart Registry. European Journal of Preventive Cardiology, 2022, 29, 1802-1810.	1.8	4
191	Clinical use of optical coherence tomography to identify angiographic silent stent thrombosis. Scandinavian Cardiovascular Journal, 2014, 48, 156-160.	1.2	3
192	Reply. Journal of the American College of Cardiology, 2015, 66, 1089-1090.	2.8	3
193	Coronary stent implantation and adverse cardiac events after surgery. European Journal of Clinical Investigation, 2018, 48, e13030.	3.4	3
194	Risk of Myocardial Infarction in Patients Without Angiographic Coronary Artery Disease Compared With the General Population. American Journal of Cardiology, 2020, 132, 8-14.	1.6	3
195	Thirteen-year trends in cardiovascular risk in men and women with chronic coronary syndrome. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 437-446.	4.0	3
196	Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions. EuroIntervention, 2019, 15, 685-687.	3.2	3
197	Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004–2016. BMC Cardiovascular Disorders, 2021, 21, 579.	1.7	3
198	Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. EuroIntervention, 2022, 17, 1348-1351.	3.2	3

#	ARTICLE	IF	CITATIONS
199	Acute haemodynamic effects of erythropoietin alone and in combination with dopamine in a porcine model. <i>Clinical Physiology and Functional Imaging</i> , 2006, 26, 283-287.	1.2	2
200	Zotarolimus-eluting versus sirolimus-eluting coronary stent implantation. <i>Interventional Cardiology</i> , 2010, 2, 807-812.	0.0	2
201	Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 84.	1.7	2
202	TCT-433 Feasibility, self-correcting properties and one-month results after implantation of a novolimus eluting bioresorbable stent in coronary bifurcations. The BIFSORB pilot study. <i>Journal of the American College of Cardiology</i> , 2016, 68, B174-B175.	2.8	2
203	Perioperative myocardial infarction: in the twilight zone between surgery and cardiology. <i>European Heart Journal</i> , 2017, 38, 2418-2420.	2.2	2
204	Risk of Myocardial Infarction and Death After Noncardiac Surgery Performed Within the First Year After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome or Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 160, 14-20.	1.6	2
205	EXCEL and NOBLE: stents or surgery for left main stem stenosis?. <i>EuroIntervention</i> , 2017, 13, e604-e608.	3.2	2
206	Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody- ϵ -covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	1.7	2
207	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	2.2	2
208	TCT-297 Stent edge dissections detected by Optical Coherence Tomography, incidence, predictors and 12-month outcome. <i>Journal of the American College of Cardiology</i> , 2012, 60, B84.	2.8	1
209	TCT-641 Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease: SORT OUT IV 5-year. <i>Journal of the American College of Cardiology</i> , 2014, 64, B186-B187.	2.8	1
210	TCT-318 Ten-year All-cause Mortality after Simple versus Complex Stenting of Coronary Artery Bifurcation Lesions in the Randomized Nordic Bifurcation Study. <i>Journal of the American College of Cardiology</i> , 2016, 68, B131-B132.	2.8	1
211	The year in cardiology 2017: coronary interventions. <i>European Heart Journal</i> , 2018, 39, 914-924.	2.2	1
212	<p>Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus [Response to Letter]<p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 721-722.	3.0	1
213	Instantaneous wave-free ratio cutoff values for nonculprit stenosis classification in patients with ST-segment elevation myocardial infarction (an iSTEMI substudy). <i>Coronary Artery Disease</i> , 2020, 31, 411-416.	0.7	1
214	Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 434-441.	3.0	1
215	Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2815-2826.	1.5	1
216	Impact of drug eluting stents on target vessel revascularization. A report from the Western Denmark heart registry from 2000 to 2004. <i>EuroIntervention</i> , 2006, 1, 391-5.	3.2	1

#	ARTICLE	IF	CITATIONS
217	Long-Term Outcomes of Perioperative Versus Nonoperative Myocardial Infarction: A Danish Population-Based Cohort Study (2000–2016). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	1
218	Intravascular ultrasound and angiographic assessment of reference segment size in type-2 diabetic patients. <i>International Journal of Cardiology</i> , 2007, 119, S27-S28.	1.7	0
219	Response to Letter Regarding Article, “Primary Angioplasty Versus Fibrinolysis in Acute Myocardial Infarction: Long-Term Follow-Up in the Danish Acute Myocardial Infarction 2 Trial”. <i>Circulation</i> , 2010, 122, .	1.6	0
220	COMMENTARY: Deliver the Drug and Disappear: Is the Bioabsorbable Magnesium Stent Growing Up or Still Shrinking?. <i>Journal of Endovascular Therapy</i> , 2011, 18, 416-417.	1.5	0
221	TCT-301 Feasibility and Results of Novel Side Branch Evaluation by Reconstructed 3-Dimensional Optical Coherence Tomography. Matched Analysis of Baseline and 12-month follow-up in Native, Jailed and Opened Side Branches. <i>Journal of the American College of Cardiology</i> , 2012, 60, B85-B86.	2.8	0
222	TCT-347 Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT OUT V Substudy. <i>Journal of the American College of Cardiology</i> , 2012, 60, B98-B99.	2.8	0
223	TCT-531 Positive Predictive Value Of Clinically Suspected ST-Segment Elevation Myocardial Infarction Using Angiographic Verification. <i>Journal of the American College of Cardiology</i> , 2012, 60, B154.	2.8	0
224	Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). <i>BMC Cardiovascular Disorders</i> , 2012, 12, 18.	1.7	0
225	TCT-598 Mechanisms of Incomplete Stent Apposition After Implantation of Drug-eluting Stents in patients with ST-segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, B181.	2.8	0
226	TCT-595 Early Healing After Treatment Of Coronary Lesions By Everolimus, Or Biolimus Eluting Bioresorbable Polymer Stents. One-month Results In The SORT-OUT VIII Optical Coherence Tomography Study. <i>Journal of the American College of Cardiology</i> , 2014, 64, B174.	2.8	0
227	Coronary stents and non-cardiac surgery: to bridge or not to bridge?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 211-213.	3.4	0
228	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2266-2267.	2.8	0
229	TCT-261 Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-eluting and Biolimus-Eluting Stents with biodegradable polymer. From the SORT OUT VII Trial. <i>Journal of the American College of Cardiology</i> , 2016, 68, B106.	2.8	0
230	TCT-321 Definite and probable stent thrombosis after revascularization with drug-eluting stents with a biodegradable polymer. From the randomized SORT OUT VII Trial. <i>Journal of the American College of Cardiology</i> , 2016, 68, B133.	2.8	0
231	TCT-347 Culprit Lesion Types and Vascular Healing in Patients with ST-segment Elevation Myocardial Infarction after Primary Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2018, 72, B141.	2.8	0
232	TCT-792 Everolimus-eluting versus biolimus-eluting stent implantation in unselected patients with and without diabetes: a SORT OUT VIII substudy. <i>Journal of the American College of Cardiology</i> , 2018, 72, B315.	2.8	0
233	TCT-290 Outcomes After Revascularization With a Polymer-Free Biolimus-Eluting BioFreedom Stent or a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT IX Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B289.	2.8	0
234	TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B11.	2.8	0

#	ARTICLE	IF	CITATIONS
235	Research update for articles published in EJCI in 2017. European Journal of Clinical Investigation, 2019, 49, e13163.	3.4	0
236	Very late Absorb scaffold thrombosis. Coronary Artery Disease, 2019, 30, 232-233.	0.7	0
237	Response to "Correspondence on "Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease" by Jong et al. Annals of the Rheumatic Diseases, 2020, , annrhumdis-2020-219231.	0.9	0
238	Reply. JACC: Cardiovascular Interventions, 2020, 13, 658-659.	2.9	0
239	Prognostic Value of Coronary Artery Calcium in Symptomatic Young Individuals Age 18 to 45 Years. Journal of the American College of Cardiology, 2021, 77, 2980-2982.	2.8	0
240	Comment on: Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population: reply. Rheumatology, 2021, 60, e419-e420.	1.9	0
241	Culprit lesion morphology in patients with ST-segment elevation myocardial infarction assessed by optical coherence tomography. Coronary Artery Disease, 2020, 31, 671-677.	0.7	0
242	Cardiovascular risks associated with smoking in patients without obstructive coronary artery disease. European Journal of Preventive Cardiology, 2022, 29, e14-e17.	1.8	0
243	CHA 2 DS 2 "VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. European Journal of Clinical Investigation, 2021, , e13717.	3.4	0
244	Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. Coronary Artery Disease, 2022, Publish Ahead of Print, .	0.7	0
245	Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0